Henchcliffe, Claire

Publications

Sort by

Co-Author Network

selected publications

A machine learning and network framework to discover new indications for small molecules. PLoS computational biology. 2020 Academic Article GET IT
Times cited: 8
Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease. CNS drugs. 2020 Review GET IT
Times cited: 5
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. JAMA neurology. 2020 Academic Article GET IT
Times cited: 5
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. 2020 GET IT
Times cited: 213
The future of stem cell therapies for Parkinson disease. Nature reviews. Neuroscience. 2020 Review GET IT
Times cited: 144
Neurophysiological Biomarkers of Parkinson's Disease. Journal of Parkinson's disease. 2020 Academic Article GET IT
Times cited: 18
Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. Frontiers in aging neuroscience. 2019 Review GET IT
Times cited: 109
Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism & related disorders. 2019 Academic Article GET IT
Times cited: 15
Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study. Scientific reports. 2019 Academic Article GET IT
Times cited: 72
18F-FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2018 Academic Article GET IT
Times cited: 21
Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2018 Review GET IT
Times cited: 51
Noninvasive PK11195-PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2018 Academic Article GET IT
Times cited: 22
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert review of clinical pharmacology. 2018 Review GET IT
Times cited: 8
Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies. Journal of Parkinson's disease. 2018 Review GET IT
Times cited: 13
Kufor-Rakeb Syndrome Due to a Novel ATP13A2 Mutation in 2 Chinese-American Brothers. 2017 GET IT
Times cited: 1
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement disorders : official journal of the Movement Disorder Society. 2017 Academic Article GET IT
Times cited: 98
Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Therapeutic advances in neurological disorders. 2016 Review GET IT
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement disorders : official journal of the Movement Disorder Society. 2016 Academic Article GET IT
Times cited: 38
Future needs for informed consent in stem cell clinical trials in neurodegenerative diseases. Neural regeneration research. 2016 Academic Article GET IT
Times cited: 4
First-in-human cell transplant trials in Parkinson's disease: The need for an improved informed consent process. Parkinsonism & related disorders. 2015 Academic Article GET IT
Times cited: 16
Dance for PD: a preliminary investigation of effects on motor function and quality of life among persons with Parkinson's disease (PD). Journal of neural transmission (Vienna, Austria : 1996). 2015 Academic Article GET IT
Times cited: 61
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA neurology. 2014 Academic Article GET IT
Times cited: 270
Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism & related disorders. 2014 Academic Article GET IT
Times cited: 20
Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2013 Academic Article GET IT
Times cited: 35
Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dementia and geriatric cognitive disorders. 2013 Academic Article GET IT
Times cited: 77
Biomarkers in Parkinson's disease: an update. Current opinion in neurology. 2012 Review GET IT
Times cited: 55
Clinical characteristics of exacerbations in Parkinson disease. The neurologist. 2012 Academic Article GET IT
Times cited: 40
Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in neurobiology. 2011 Review GET IT
Times cited: 27
The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain : a journal of neurology. 2011 Review GET IT
Times cited: 153
Disease modification in Parkinson's disease. Drugs & aging. 2011 Review GET IT
Times cited: 35
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clinical ophthalmology (Auckland, N.Z.). 2010 Academic Article GET IT
Times cited: 103
Clinical predictors of frequent patient telephone calls in Parkinson's disease. Parkinsonism & related disorders. 2010 Academic Article GET IT
Times cited: 17
How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ET on medication: data from 528 patients in three settings. European journal of neurology. 2010 Academic Article GET IT
Times cited: 71
Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatric disease and treatment. 2009 Academic Article GET IT
Mirror movements in patients with essential tremor. Movement disorders : official journal of the Movement Disorder Society. 2009 Academic Article GET IT
Times cited: 16
Metabolomic profiling in LRRK2-related Parkinson's disease. PloS one. 2009 Academic Article GET IT
Times cited: 127
Older onset essential tremor: More rapid progression and more degenerative pathology. Movement disorders : official journal of the Movement Disorder Society. 2009 Academic Article GET IT
Times cited: 64
Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Annals of the New York Academy of Sciences. 2008 Review GET IT
Times cited: 54
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature clinical practice. Neurology. 2008 Review GET IT
Times cited: 600
Cancer and blood concentrations of the comutagen harmane in essential tremor. Movement disorders : official journal of the Movement Disorder Society. 2008 Academic Article GET IT
Times cited: 9
Rasagiline in treatment of Parkinson's disease. Neuropsychiatric disease and treatment. 2008 Academic Article GET IT
Case study of an unusual variant of restless leg syndrome. Movement disorders : official journal of the Movement Disorder Society. 2008 Letter GET IT
Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor. Neurotoxicology. 2007 Academic Article GET IT
Times cited: 73
Young-onset Parkinson's disease: hospital utilization and medical comorbidity in a nationwide survey. Neuroepidemiology. 2007 Academic Article GET IT
Times cited: 11
Retraction. Young-onset Parkinson's disease: hospital utilization and medical comorbidity in a nationwide survey. Movement disorders : official journal of the Movement Disorder Society. 2007 Academic Article GET IT
Excitotoxicity. Handbook of clinical neurology. 2007 Academic Article GET IT
Times cited: 2
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 139
Late-life depression: a neuropsychiatric approach. Expert review of neurotherapeutics. 2006 Review GET IT
Times cited: 20
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert review of neurotherapeutics. 2005 Review GET IT
Times cited: 38
Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system. Journal of neurology, neurosurgery, and psychiatry. 2005 Academic Article GET IT
Times cited: 74
Entacapone in the management of Parkinson's disease. Expert opinion on pharmacotherapy. 2002 Review GET IT
Times cited: 8
Expression of c-fos, c-jun, and c-jun N-terminal kinase (JNK) in a developmental model of induced apoptotic death in neurons of the substantia nigra. Journal of neurochemistry. 1999 Academic Article GET IT
Times cited: 77
Increased expression of cyclin-dependent kinase 5 in induced apoptotic neuron death in rat substantia nigra. Neuroscience letters. 1997 Academic Article GET IT
Times cited: 47
Neuron death in the substantia nigra of weaver mouse occurs late in development and is not apoptotic. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1996 Academic Article GET IT
Times cited: 51
Apoptosis in substantia nigra following developmental hypoxic-ischemic injury. Neuroscience. 1995 Academic Article GET IT
Times cited: 66
Genetic analysis of laminin A reveals diverse functions during morphogenesis in Drosophila. Development (Cambridge, England). 1993 Academic Article GET IT
Times cited: 85
Cell type specific trans-acting factors are involved in alternative splicing of human fibronectin pre-mRNA. The EMBO journal. 1989 Academic Article GET IT
Times cited: 30
Sequence analysis and in vivo expression show that alternative splicing of ED-B and ED-A regions of the human fibronectin gene are independent events. Nucleic acids research. 1988 Academic Article GET IT
Times cited: 23

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Quantitative Mapping of Substantia Nigra Iron in Parkinson''s Disease awarded by National Institute of Neurological Disorders & Stroke Co-Investigator 2016 - 2024
Predictive Model of Spread of Parkinson''s Pathology Using Network Diffusion awarded by National Institute of Neurological Disorders & Stroke Co-Investigator 2016 - 2023

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) awarded by National Institute of Environmental Health Sciences Co-Principal Investigator 2018 - 2023

more ...

less ...

Background

education and training

M.D., Columbia University College of Physicians and Surgeons 1997
D.Phil., Oxford University (United Kingdom) 1992
M.A., Oxford University (United Kingdom) 1988
B.A., Oxford University (United Kingdom) 1985

Contact

full name

Claire Henchcliffe

primary email

clh2007@med.cornell.edu

VIVO Weill Cornell Medical College

Claire Henchcliffe Adjunct Professor of Neurology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email